RxDoctor Payments Data

Michael Ginnetti, MD

Dermatology · Bloomington, ILNPI 1316474976

Payments from drug & device makers

$4,562in general payments, 2019–2025

Across 226 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • UCB, Inc.$837
  • Sun Pharmaceutical Industries Inc.$400
  • Lilly USA, LLC$285
  • Regeneron Healthcare Solutions, Inc.$246
  • Organogenesis Inc.$206
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,01188%
  • Education$55112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,562 in reported general payments places this provider in the 60th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$753,945
Medicare patients
818
Services billed
6,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$75,831
Dupixent PenDupilumab12$45,903
Fluorouracil102$7,369
Clobetasol Propionate133$7,163
Fluocinonide92$3,049
Ketoconazole251$2,929
Calcipotriene21$2,559
Tacrolimus26$1,845
Triamcinolone Acetonide236$1,664
Doxycycline Monohydrate73$1,522
Clindamycin Phosphate41$1,375
Fluocinolone Acetonide20$1,347
Tretinoin14$942
Metronidazole22$836
Pregabalin12$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$107$75,83116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 606 dermatology providers in Illinois.

Other dermatology in Bloomington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →